JP2017534577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534577A5 JP2017534577A5 JP2017514474A JP2017514474A JP2017534577A5 JP 2017534577 A5 JP2017534577 A5 JP 2017534577A5 JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017534577 A5 JP2017534577 A5 JP 2017534577A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- cdr
- pdl1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050745P | 2014-09-15 | 2014-09-15 | |
| US62/050,745 | 2014-09-15 | ||
| PCT/US2015/050051 WO2016044189A1 (en) | 2014-09-15 | 2015-09-14 | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020143036A Division JP2021001176A (ja) | 2014-09-15 | 2020-08-26 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017534577A JP2017534577A (ja) | 2017-11-24 |
| JP2017534577A5 true JP2017534577A5 (Direct) | 2018-10-25 |
Family
ID=54325043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514474A Withdrawn JP2017534577A (ja) | 2014-09-15 | 2015-09-14 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
| JP2020143036A Pending JP2021001176A (ja) | 2014-09-15 | 2020-08-26 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020143036A Pending JP2021001176A (ja) | 2014-09-15 | 2020-08-26 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20170274073A1 (Direct) |
| EP (1) | EP3194440A1 (Direct) |
| JP (2) | JP2017534577A (Direct) |
| CN (1) | CN106687135A (Direct) |
| WO (1) | WO2016044189A1 (Direct) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| WO2017136497A1 (en) * | 2016-02-03 | 2017-08-10 | The Cleveland Clinic Foundation | Detection and treatment of il-17 and il-13 related conditions |
| EP3440219B1 (en) * | 2016-04-08 | 2021-09-01 | Centre National De La Recherche Scientifique | Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| US20190270802A1 (en) * | 2016-10-21 | 2019-09-05 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist |
| WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| KR102713355B1 (ko) * | 2017-05-25 | 2024-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | 길항작용 cd40 모노클로날 항체 및 그의 용도 |
| EP3641813A4 (en) | 2017-06-18 | 2021-04-21 | Kindred Biosciences, Inc. | IL17A ANTIBODIES AND ANTAGONISTS FOR USE IN VETERINARY MEDICINE |
| BR112020002871A2 (pt) | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| CN111770936A (zh) * | 2018-01-12 | 2020-10-13 | 百时美施贵宝公司 | 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症 |
| WO2019152344A1 (en) * | 2018-01-30 | 2019-08-08 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating inflammation and cancer |
| JP2021524744A (ja) * | 2018-05-21 | 2021-09-16 | ナノストリング テクノロジーズ，インコーポレイティド | 分子遺伝子シグネチャーとその使用方法 |
| CN110563842B (zh) * | 2018-06-06 | 2022-07-29 | 浙江博锐生物制药有限公司 | 针对程序性死亡配体(pd-l1)的抗体及其应用 |
| KR102091637B1 (ko) * | 2018-07-10 | 2020-03-20 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN109053891B (zh) | 2018-09-17 | 2021-12-21 | 苏州泓迅生物科技股份有限公司 | 一种抗pd-l1抗体及其制备方法和应用 |
| WO2020150208A1 (en) * | 2019-01-14 | 2020-07-23 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors |
| JP7795737B2 (ja) * | 2019-04-03 | 2026-01-08 | オレガ・バイオテック | Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法 |
| WO2020218322A1 (ja) * | 2019-04-23 | 2020-10-29 | 国立大学法人東北大学 | 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測 |
| WO2021202959A1 (en) * | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| MX2022013649A (es) * | 2020-04-30 | 2023-02-01 | Janssen Pharmaceutica Nv | Métodos para identificar moduladores de la ruta de il-17. |
| US20240400668A1 (en) * | 2022-07-29 | 2024-12-05 | Jinfeng Laboratory | Non-human mammalian model expressing il-8 and use thereof |
| WO2025003035A1 (en) * | 2023-06-30 | 2025-01-02 | Universitätsklinikum Essen | Il-17 based therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2011141823A2 (en) * | 2010-05-14 | 2011-11-17 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| TWI835048B (zh) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| EP2744825A1 (en) * | 2011-08-17 | 2014-06-25 | F.Hoffmann-La Roche Ag | Inhibition of angiogenesis in refractory tumors |
| KR101463325B1 (ko) * | 2013-01-14 | 2014-11-20 | 가톨릭대학교 산학협력단 | HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물 |
-
2015
- 2015-09-14 JP JP2017514474A patent/JP2017534577A/ja not_active Withdrawn
- 2015-09-14 WO PCT/US2015/050051 patent/WO2016044189A1/en not_active Ceased
- 2015-09-14 EP EP15780971.6A patent/EP3194440A1/en not_active Withdrawn
- 2015-09-14 CN CN201580048941.5A patent/CN106687135A/zh active Pending
-
2017
- 2017-03-02 US US15/448,437 patent/US20170274073A1/en not_active Abandoned
-
2019
- 2019-06-26 US US16/453,650 patent/US20200155676A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,805 patent/US20200405855A1/en not_active Abandoned
- 2020-08-26 JP JP2020143036A patent/JP2021001176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534577A5 (Direct) | ||
| JP2017501167A5 (Direct) | ||
| FI4141032T3 (fi) | T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito | |
| JP2023123726A5 (Direct) | ||
| JP2020500538A5 (Direct) | ||
| JP2016510002A5 (Direct) | ||
| JP2017514461A5 (Direct) | ||
| JP2018035138A5 (Direct) | ||
| JP2015509947A5 (Direct) | ||
| JP2016505546A5 (Direct) | ||
| JP2018521638A5 (Direct) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2017507900A5 (Direct) | ||
| JP2018108081A5 (Direct) | ||
| JP2017113028A5 (Direct) | ||
| JP2017501157A5 (Direct) | ||
| JP2014158469A5 (Direct) | ||
| JP2018508483A5 (Direct) | ||
| JP2013198490A5 (Direct) | ||
| JP2017528476A5 (Direct) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| JP2018505177A5 (Direct) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2014511179A5 (Direct) | ||
| JP2018507220A5 (Direct) |